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Summary Vascular endothelial growth factor (VEGF) expression, vascularisation and tumour cell
proliferation were analysed in 91 human epidermoid lung carcinomas using immunohistochemistry. A
polyclonal anti-VEGF antibody was used for VEGF expression, a polyclonal antibody directed against human
von Willebrand factor (factor VIII) to identify blood vessels and the proliferating cell nuclear antigen (PCNA)
as a marker for proliferating cells. Positive staining for VEGF was obtained in 54 out of 91 cases (59%), the
number of blood vessels varied from zero to 64 counts (mean 9.4) and the proportion of PCNA-positive cells
varied from 1.3% to 72.1% (mean 25.2%). The mean PCNA labelling index and mean microvessel count in
VEGF-positive tumours were significantly higher than those in VEGF-negative tumours (Wilcoxon rank sum
test, P<0.0001; P<0.05). In addition, PCNA labelling index significantly increased with increasing VEGF
expression (Jonckheere test, P<0.0001). In contrast, no association was found between PCNA labelling index
and tumour vascularity (r=0.07, P=0.48). The close correlation of VEGF expression with tumour cell
proliferation and microvessel density suggests that VEGF acts both as an autocrine growth factor and as
stimulator for angiogenesis. However, tumour cell proliferation and microvessel growth and/or density may be
regulated by separate mechanisms.
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Angiogenesis, the development and formation of new blood
vessels, is important in a variety of physiological processes,
such as growth and differentiation, ovulation, wound healing
and neoplasia (Folkman and Klagsbrun, 1987; Folkman and
Shing, 1992). Increased vascular density has been shown to
correlate with a higher incidence of metastases and a worse
prognosis in breast cancer (Weidner et al., 1991; Toi et al.,
1993), lung cancer (Macchiarini et al., 1992; Yamazaki et al.,
1994), melanoma (Srivastava et al., 1988), and in tumours of
the prostate (Weidner et al., 1993). Vascular proliferation is a
requirement for solid tumour growth and is induced by
angiogenic factors produced by the tumour or non-malignant
cells. However, the mechanisms underlying angiogenesis in
tumours are incompletely understood. Various growth factors
have been shown to stimulate angiogenesis, including
fibroblast factors, transforming growth factor (TGF)-oc,
platelet-derived growth factor (PDGF) and vascular endothe-
lial growth factor (VEGF). The relative importance of the
individual angiogenic factors in most tumour types is still
largely unclear.
Recent results with basic fibroblast growth factor (bFGF)
in melanoma (Becker et al., 1989), embryonal rhabdomyo-
sarcoma (Schweigerer et al., 1987) and ovarian carcinoma
(Crickard et al., 1994) suggest that tumour cells produce and
release bFGFs and the released bFGFs can stimulate their
own proliferation as well as the proliferation of the vascular
endothelial cells. These results prompted us to investigate the
association between VEGF expression, tumour cell prolifera-
tion and angiogenesis in human lung carcinomas. It could be
that VEGF might act similarly to bFGF as a self-stimulating
growth factor, i.e. tumour cells produce VEGF which
stimulates their own growth and that of vascular endothelial
cells.
In this study, we report on the VEGF expression and its
relationship to the frequency of tumour cell proliferation and
tumour vascularity in 91 epidermoid lung carcinomas using
immunohistochemistry and antibodies to VEGF, proliferat-
ing cell nuclear antigen (PCNA) and endothelium (factor
VIII).
Material and methods
Tumours
Tumour specimens from 91 patients with previously
untreated epidermoid lung carcinoma who had been
surgically treated at the Heidelberg-Rohrbach Chest Hospi-
tal were analysed for tumour cell proliferation, VEGF
expression and microvessel density. The histological classifi-
cation of the tumours was based on the guidelines of the
World Health Organization (1981). The mean age of the
patients was 59 years (range 37-75), seven were female and
84 were male. Of the 91 patients, 14 had stage I, 10 stage II
and 67 stage III tumours, according to the guidelines of the
American Joint Committee for Cancer Staging and End
Results Reporting (Carr and Mountain, 1977).
Determination of VEGF expression
Staining for VEGF protein was performed using a
commercially available polyclonal anti-VEGF antibody (Ab-
2; Dianova, Hamburg, Germany), generated by immunising
rabbits with a peptide from the N-terminal region of
VEGF165, and using a previously established method (Volm
et al., 1991). Briefly, formalin-fixed, paraffin-embedded 5 gm
sections were rehydrated and incubated overnight at 4°C with
the primary antibody diluted 1:10. Biotinylated anti-rabbit
IgG (1:50) and a complex of streptavidin and biotinylated
peroxidase (1:100) were added in sequence. The peroxidase
activity was visualised with 3-amino-9-ethylcarbazole. Coun-
terstaining was performed with haematoxylin. To suppress
endogenous peroxidase and biotin activity and to block non-
specific binding sites preincubation of the samples was
performed with hydrogen peroxide, unlabelled streptavidin
and non-immunised normal serum. Negative controls were
carried out by omitting the primary antibody and by
substituting the primary antibody with an irrelevant anti-
body.
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For evaluation of VEGF expression a score corresponding
to the sum of both (a) staining intensity (0=negative;
=weak; 2 =intermediate; 3= strong) and (b) percentage of
positive cells (0=0% positive cells; 1= <25% positive cells;
2 =26-50% positive cells; 3= >50% positive cells) was
established. The sum of (a)+(b) reached a maximum score
of 6. A score greater than 2 was the value of a positive
immunohistochemical assay.
Determination of tumour cell PCNA labelling index
Nuclei of proliferating cells were stained with the antibody
for the proliferating cell nuclear antigen (PCNA) (Dianova;
clone PClO) in a dilution 1:10. This antibody reacts with the
amino acid sequence 185-195 of the PCNA peptide (Roos et
al., 1993). Tumour cell proliferation was scored by selecting
the maximally immunostained areas and counting PCNA-
positive and -negative tumour cells at x 400 magnification
and with an eyepiece grid. All reactive cells were counted as
positive regardless of the intensity of staining. In each case, a
minimum of 500 cells were counted and the fraction of
positive cells was determined. The cases were scored without
knowledge of other clinical parameters.
Determination ofmicrovessel density
Intratumoral blood vessels were highlighted by staining
endothelial cells with anti-human factor VIII antibody
(Dako Diagnostika, Hamburg, Germany) in a dilution 1:20
and incubating overnight. Microvessel density was deter-
mined as described by Weidner et al. (1991) in the area of
most intense vascularisation (hotspot) of each tumour.
Individual microvessel counts were then made on a 250x
field (25 x objective and 10 x ocular, corresponding to an area
of 0.363 mm2) by three independent observers. The average
count from the three observers was used as the final score.
Statistical analysis
To determine whether there was a significant difference
between PCNA labelling index or microvessel density in
VEGF-positive tumours vs VEGF-negative tumours, the
Wilcoxon rank sum test was used. In addition, to examine
the relationship between VEGF expression and PCNA
labelling index, the Jonckheere test was used which tests the
equality of the medians against the ordered alternatives
(Hollander and Wolfe, 1973). The relationship of PCNA
labelling index and microvessel density was assessed
statistically by using linear regression analysis.
Results
VEGF expression and tumour cell proliferation
Ninety-one epidermoid lung carcinomas were analysed by
immunohistochemistry with antibodies to vascular endothe-
lial growth factor (VEGF) and proliferating cell nuclear
antigen (PCNA). Positive staining for VEGF was obtained in
54 out of 91 cases (59%). The expression of VEGF was
mainly identified in the cytoplasma of tumour cells. In Figure
1a two nests with predominantly cytoplasmatic immuno
reactivity are shown. A weak positive VEGF staining was
also seen on endothelial cells. Proliferating tumour cells were
easily identified by nuclear immunostaining with the PCNA
antibody (Figure lb). The mean PCNA labelling index of all
tumours was 25.2% + 18.2% (median, 24; range, 1.3-72.1),
measured in the maximally PCNA immunostained areas. The
PCNA labelling index (mean + s.d.) in VEGF-positive
tumours (score 3-6) was significantly higher than that in
VEGF-negative tumours (score 0-2) (36.2% + 15.8% vs
10.1%+6.9%; Wilcoxon rank sum test, P<0.0001; Table
I). PCNA labelling index significantly increased with
increasing VEGF score (Jonckheere test, P<0.0001) (Figure
2).
VEGF expression and microvessel density
The mean microvessel count in a 250 x field for all tumours
was 9.4 + 10.1 (median, 6; range, 0-64). The areas of high
vascularisation occurred most frequently at the margins of
the carcinomas. An example of microvessel staining with
factor VIII is shown in Figure Ic. The microvessel count
(mean + s.d.) in VEGF-positive tumours was significantly
higher than that in VEGF-negative tumours (10.9 + 11.2 vs
5.7 + 3.9; Wilcoxon rank sum test, P<0.05; Table I).
Tumour cellproliferation and microvessel density
Tumour cell proliferation, as assessed by the PCNA labelling
index in the maximally immunostained areas, was correlated
with tumour vessel density, measured in the vascular
hotspots. There was no association between tumour cell
PCNA labelling index and tumour vascularity (r =0.07,
P=0.48) (Figure 3).
Figure 1 Immunohistochemical staining ofan epidermoid lung carcinoma with anti-VEGF antibody (a). Two nests (arrows) are shown with
predominantly cytoplasmatic immunoreactivity ( x 100). Immunohistochemical staining with anti-PCNA antibody (b). Immunoreactivity was
confined to the nuclei of tumour cells (arrows) (x 250). Immunohistochemical staining with antibody to factor VIII-related antigen (c).
Arrow points to a representative microvessel within the carcinoma showing staining of the vascular epithelium (x 250). Counterstaining was
performed with haematoxylin.Table I Association between VEGF expression
proliferation and angiogenesis
and tumour cell
VEGF VEGF Wilcoxon
positive negative rank sum
(score 3-6) (score 0-2) P
PCNA LI
Mean 36.2 10.1
Median 33.5 8 0.0001
Range 6-78 1 -34
s.d. 15.8 6.9
Vessel density
Mean 10.9 5.7
Median 7 5
Range 0-64 0-16 0.05
s.d. 11.2 3.9
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Figure 2 Relationship between VEGF expression (score 0-6)
and PCNA labelling index (%) in human epidermoid lung
carcinomas (n =91). Numbers in parenthesis represent number
of patients in the subgroups. The mean value of each group is
shown by a horizontal line. Jonckheere test P<0.0001.
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Figure 3 Relationship between microvessel count and PCNA
labelling index in human epidermoid lung carcinomas (n=91).
r =0.07, P=0.48.
Discussion
In this study we have examined the relationship of vascular
endothelial growth factor (VEGF) expression to tumour cell
proliferation and microvessel density in human epidermoid
lung carcinomas. The present results indicate that the
proliferation of the tumours is closely related to their
expression of VEGF. These findings are consistent with the
VEGF, angiogenesis and tumour proliferation
J Mattern et al
933
observation that human MCF-7 cells transfected with VEGF
and xenografted subcutaneously into nude mice formed faster
growing tumours than did wild-type cells and have greater
vascular density compared with those formed by wild-type
MCF-7 cells (Zhang et al., 1995). Also HeLa cells, transfected
with VEGF, showed higher angiogenic activity, take rate and
faster tumour growth than the control transformant when
they were implanted to nude mice (Kondo et al., 1993).
Recently, Becker et al. (1989) demonstrated that prolifera-
tion of human melanoma cells is dependent upon autocrine
production of bFGF. Exposure of melanomas to antisense
oligodeoxynucleotides targeted against human bFGF mRNA
inhibited cell proliferation and colony formation in soft agar.
The possibility that bFGF could act as a paracrine and/or
autocrine growth factor was also suggested by Schweigerer et
al. (1987) and Crickard et al. (1994), who demonstrated that
human tumour cells can produce bFGFs and have the ability
to respond to bFGFs in stimulating their own growth and
that of vascular endothelial cells. Sporn and Roberts (1985)
proposed the term 'autocrine secretion' which is the ability of
cells to produce and to respond to their own growth factors.
The close relationship between VEGF expression and tumour
cell proliferation in this study suggests that possibly VEGF
could act similarly to bFGF or in a synergistic manner with
bFGF (Goto et al., 1993) as an autocrine growth factor in
human lung tumours. Four VEGF isoforms (VEGF121,
VEGF165, VEGF189 and VEGF206) have been described in
humans. VEGF165 is the most abundant isoform (Ferrara et
al., 1992). However, the significance of the various VEGF
isoforms is unknown. Perhaps the different VEGF isoforms
have different affinities to their receptors or may mediate
distinct functions. The binding of VEGF to its receptors is
dependent on cell surface-associated heparin-like molecules
(Gitay-Goren et al., 1992). The enhancing effect of heparin
facilitates the detection of VEGF receptors on cell types that
were not known previously to express such receptors (Gitay-
Goren et al., 1992).
To investigate whether VEGF is involved in lung tumour
angiogenesis, the data of VEGF expression were correlated
with vessel density. We found that the expression of VEGF
was closely associated with the increment of vessel density.
These data clearly support the role of VEGF as a mitogenic
growth factor for vascular endothelial cells also in lung
carcinomas. However, it is clear that the vascular phenotype
in any tumour will be the result of a large number of factors
influencing angiogenesis, but our correlation suggests that
VEGF is at least one of the important factors governing
angiogenesis in lung carcinomas.
The mitogenic activity of VEGF seemed to be restricted to
vascular endothelial cells (Conolly et al., 1989; Senger et al.,
1993), and initial characterisation of VEGF receptors was
therefore carried out using these cells. In the meantime,
however, VEGF receptors were also detected on non-vascular
endothelial cells such as HeLa cells, NIH3T3 cells (Gitay-
Goren et al., 1992), on several cell lines of human melanomas
(Gitay-Goren et al., 1993), and recently on ovarian
carcinoma cells (Boocock et al., 1995), but the function of
the VEGF receptors in these cells is still unclear. Whether the
receptors known so far mediate the proliferation enhancing
effects of VEGF and whether they represent the only
receptors for this family of factors remains to be established.
Because the growth of solid tumours needs an adequate
vascular network for supply of oxygen and nutrients and in
order to remove waste products, the vascular density and its
influence on tumour cell proliferation was analysed in human
epidermoid lung carcinomas. Although it has been estab-
lished that tumour cell proliferation decreases with increasing
distances from the blood vessels (Tannock, 1968), microvessel
density has not correlated with tumour cell proliferation in
this study. Our results with lung carcinomas are consistent
with studies of others in breast cancer (Fox et al., 1993;
Vartanian and Weidner, 1994) and carcinoma of the
oesophagus (Porschen et al., 1994), who found no correla-
tion of microvessel density with tumour cell proliferation or
uL20-
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intratumoral endothelial cell proliferation. In contrast,
Vermeulen et al. (1995) found an association between
tumour cell labelling index, measured in the maximally Ki-
67 immunostained areas, and tumour vascularity, measured
in the vascular hotspots in colorectal adenocarcinomas, when
a complete cross-section of the tumour was scanned. Taken
together, the data suggest that growth factors controlling
tumour growth are not the same as those involved in
endothelial cell growth and that tumour cell proliferation and
microvessel growth and/or density may be regulated by
different mechanisms (Vartanian and Weidner, 1994).
Angiogenesis is a complex process that involves endothelial
cell migration, capillary budding, neovascular remodelling, in
addition to endothelial cell proliferation. The lack of
correlation between microvessel density and tumour cell
proliferation in our study and in the studies of others (Fox et
al., 1993; Vartanian and Weidner, 1994; Porschen et al.,
1994) supports this concept.
In conclusion, the close correlation of VEGF expression
with tumour cell proliferation and angiogenesis in epidermoid
lung carcinomas suggests that VEGF may act similarly to
bFGFs as both a direct autocrine growth factor for their own
tumour growth and as an indirect mediator of growth by
stimulating tumour angiogenesis. Furthermore, the lack of
correlation between tumour cell proliferation and intratu-
moral microvessel density indicates that tumour cell
proliferation and microvessel growth and/or density may be
regulated by separate mechanisms.
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